Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IMS Health, VNU In Talks To End Merger Agreement

This article was originally published in The Pink Sheet Daily

Executive Summary

VNU says 48% of shareholders have indicated they would not support the $7 bil. acquisition.

You may also be interested in...



IMS Health, VNU Terminate Merger Agreement Due To Stockholder Dissatisfaction

The two firms will continue to collaborate on joint projects that were initiated before the July merger agreement.

IMS Health, VNU Terminate Merger Agreement Due To Stockholder Dissatisfaction

The two firms will continue to collaborate on joint projects that were initiated before the July merger agreement.

IMS Health To Be Acquired By Market Research Firm VNU

Acquisition of IMS Health will allow Netherlands-based VNU to move its health care marketing segment into physician targeting. The $7 bil. deal is expected to close in the first quarter of 2006.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel